12:00 AM
Jun 17, 2013
 |  BioCentury  |  Finance

Broader spectrum

Japanese investors hope Prism's expansion beyond cancer will double valuation
Broader spectrum

Prism Pharma Co. Ltd. plans to use the $15 million it raised in a series C round last week to expand the Japanese company's focus beyond cancer and beef up its valuation.

New investor Innovation Network Corp. of Japan led the round with participation from existing investors DBJ Capital Co. Ltd., the Organization for Industry-Academia-Government Collaboration (Collabo SGK), JAFCO Co. Ltd., Neostella Capital Co. Ltd. and Angel Capital Co. Ltd.

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >